PDF icon PDF herunterladen
Am J Perinatol 2024; 41(13): 1748-1754
DOI: 10.1055/a-2308-2220
SMFM Fellowship Series Article

Buccal versus Vaginal Misoprostol Combined with a Foley Catheter among Individuals with Obesity Undergoing Induction

Helen B. Gomez Slagle 
1   Department of Maternal Fetal Medicine, Columbia University Irving Medical Center, New York, New York
,
Tetsuya Kawakita
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Matthew K. Hoffman 
3   Department of Obstetrics and Gynecology, ChristianaCare, Newark, Delaware
,
Anthony C. Sciscione
3   Department of Obstetrics and Gynecology, ChristianaCare, Newark, Delaware
4   Delaware Center for Maternal Fetal Medicine, Division of Maternal Fetal Medicine, Newark, Delaware
,
Marwan Ma'ayeh
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar aufeRefHebammen
   Lizenzen und Reprints
Preview

Abstract

Objective Combining pharmacologic agents with mechanical ripening achieves the shortest labor duration, yet there is no clear evidence on route of drug administration in obese individuals. The use of buccal misoprostol has shown greater patient acceptance but remains understudied. Our objective was to evaluate the difference in time to delivery of buccal compared with vaginal misoprostol in combination with a Foley catheter (FC) for induction of labor (IOL) in the obese population.

Study Design This was a secondary analysis of a randomized controlled trial comparing identical dosages (25 μg) of buccal and vaginal misoprostol in combination with a FC. The parent trial was an institutional review board-approved, randomized clinical trial conducted from June 2019 through January 2020. Labor management was standardized among participants. Women undergoing IOL at ≥37 weeks with a singleton gestation and cervical dilation ≤2 cm were included. Body mass index (BMI, kg/m2) was stratified. The primary outcome was time to delivery.

Results A total of 215 participants were included. Demographic characteristics were similar between the three groups. Vaginal drug administration achieved a faster median time to delivery than the buccal route among patients with a body mass index greater than or equal to 30 kg/m2 (vaginal misoprostol–FC: 21.3 hours vs. buccal misoprostol–FC: 25.2 hours, p = 0.006). There was no difference in the cesarean delivery rate between the two groups. Furthermore, patients with a BMI greater than or equal to 30 kg/m2 receiving vaginal misoprostol delivered 1.2 times faster than women who received buccal misoprostol after censoring for cesarean delivery and adjusting for parity (hazard ratio: 1.2, 95% confidence interval: 1.1–1.7). There were no significant differences in maternal and neonatal outcomes.

Conclusion We found that vaginal misoprostol was superior to buccal misoprostol when combined with a FC among individuals with a BMI greater than or equal to 30 kg/m2. Vaginal misoprostol should be the preferred route of drug administration for term IOL in this population.

Key Points

  • Vaginal misoprostol was superior to buccal route among patients with obesity.

  • There was no difference in the cesarean delivery rate between the two groups.

  • Vaginal misoprostol should be the preferred route of administration among patients with obesity.

Keywords

labor induction - obesity - misoprostol - buccal - Foley - cervical ripening - vaginal

Note

Vaginal misoprostol leads to faster delivery compared with buccal dosing in combination with mechanical ripening among individuals with obesity. Buccal misoprostol is commonly used for cervical ripening but route of misoprostol administration for term IOL remains understudied in individuals with obesity. Individuals with a body mass index greater than or equal to 30 kg/m2 receiving vaginal misoprostol combined with Foley catheter had faster time to delivery by any mode, shorter time to vaginal delivery, and active labor compared with individuals receiving buccal misoprostol with Foley. Vaginal misoprostol is superior to buccal misoprostol for preinduction cervical ripening at term in individuals with a body mass index greater than 30 kg/m2.


Prior Presentation

This manuscript data were previously published as poster Presentation at SMFM's 43rd Annual Pregnancy Meeting, February 6–11, 2023.


Clinical Trial Registration

This study is registered with ClinicalTrials.gov NCT03976037.




Publikationsverlauf

Eingereicht: 22. Februar 2024

Angenommen: 09. April 2024

Accepted Manuscript online:
17. April 2024

Artikel online veröffentlicht:
10. Mai 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA